8-KRegulation FDOther EventsExhibits & Filings

Cencora, Inc. 8-K Report, Regulation FD Disclosure (Dec 15, 2025)

Filed December 15, 2025For Securities:COR

Summary

Cencora, Inc. (COR) has announced a significant strategic acquisition, agreeing to purchase the majority of the outstanding equity interests it doesn't currently own in OneOncology. This move is expected to cost approximately $3.6 billion for the equity, plus the retirement of $1.3 billion in existing corporate debt, totaling $5.0 billion in cash consideration. The acquisition aims to bolster Cencora's position in the oncology market by integrating OneOncology's physician-led national platform, which supports independent medical specialty practices. OneOncology's affiliated practices and management will retain a minority stake. The transaction is slated to be funded through new debt financing, with $4.5 billion in bridge financing commitments secured, and is contingent upon customary closing conditions, including regulatory approvals.

Key Highlights

  • 1Cencora (COR) to acquire majority equity interests in OneOncology for approximately $3.6 billion.
  • 2Total transaction cost, including $1.3 billion debt retirement, amounts to $5.0 billion in cash.
  • 3OneOncology's existing practices and management will retain a minority interest.
  • 4The acquisition is financed through new debt, with $4.5 billion in bridge financing commitments obtained.
  • 5Transaction is subject to customary closing conditions and regulatory approvals.
  • 6The press release was issued on December 15, 2025, and the agreement was entered into on December 12, 2025.
  • 7This move aims to strengthen Cencora's presence in the oncology sector through OneOncology's independent practice platform.

Frequently Asked Questions

The primary purpose of this acquisition is to significantly expand Cencora's presence and capabilities within the oncology market by integrating OneOncology, a national platform that supports independent medical specialty practices led by physicians.

Cencora plans to finance the transaction through new debt financing. The company has already secured $4.5 billion in bridge financing commitments to facilitate the acquisition.

Yes, OneOncology's affiliated practices and management will retain a minority interest in OneOncology following the acquisition by Cencora.

The transaction is subject to the satisfaction of customary closing conditions. This includes obtaining the necessary regulatory approvals, which are a key hurdle before the deal can be finalized.